UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041845
Receipt number R000047769
Scientific Title Effect of Fexofenadine/Pseudoephedrine combination tablet on Nasal Obstruction in Patients with Allergic Rhinitis
Date of disclosure of the study information 2020/09/18
Last modified on 2020/09/18 19:31:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Fexofenadine/Pseudoephedrine combination tablet on Nasal Obstruction in Patients with Allergic Rhinitis

Acronym

Effect of Fexofenadine/Pseudoephedrine combination tablet on Nasal Obstruction in Patients with Allergic Rhinitis

Scientific Title

Effect of Fexofenadine/Pseudoephedrine combination tablet on Nasal Obstruction in Patients with Allergic Rhinitis

Scientific Title:Acronym

Effect of Fexofenadine/Pseudoephedrine combination tablet on Nasal Obstruction in Patients with Allergic Rhinitis

Region

Japan


Condition

Condition

allergic rhinitis

Classification by specialty

Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

we estimated the efficacy of fexofenadine/pseudoephedrine on nasal obstruction in patients with perennial allergic rhinitis versus fexofenadine using objective methods.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

nasal airflow

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

measure nasal airflow for 8 hours at 30-minute intervals after taking a single agent: fexofenadine/pseudoephedrine combination tablet

Interventions/Control_2

measure nasal airflow for 8 hours at 30-minute intervals after taking a single agent:fexofenadine

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) with a history of allergic rhinitis
(2) with nasal obstruction
(3) house dust mite allergy based on skin reactions or serum allergen-specific IgE antibody measurements.

Key exclusion criteria

(1) upper respiratory tract infection
(2) allergen-specific immunotherapy
(3) pregnancy, or lactation
(4) patients with hypertension, severe asthma
(5)a history of known hypersensitivity, allergic reactions

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Hiromi
Middle name
Last name Takeuchi

Organization

Tottori University

Division name

Division of Otolaryngology, Head and Neck Surgery, Department of Medicine of Sensory and Motor Organ

Zip code

683-8503

Address

36-1, Nishi-cho, Yonago

TEL

0859-38-6627

Email

oto3175@tottori-u.ac.jp


Public contact

Name of contact person

1st name Yosuke
Middle name
Last name Nakamura

Organization

Faculty of Medicine, Tottori University

Division name

Division of Otolaryngology, Head and Neck Surgery, Department of Medicine of Sensory and Motor Organ

Zip code

683-8504

Address

36-1, Nishi-cho, Yonago

TEL

0859-38-6627

Homepage URL


Email

yosuken@tottori-u.ac.jp


Sponsor or person

Institute

Tottori University

Institute

Department

Personal name



Funding Source

Organization

self-funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Faculity of Medicine,Tottori university

Address

36-1 Nishi-cho, Yonago

Tel

0859-38-7108

Email

me-kenkyu@ml.adm.tottori-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 09 Month 18 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled

24

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2013 Year 07 Month 08 Day

Date of IRB

2013 Year 07 Month 08 Day

Anticipated trial start date

2016 Year 01 Month 01 Day

Last follow-up date

2020 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 09 Month 18 Day

Last modified on

2020 Year 09 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047769


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name